Frontiers in Immunology · Published 2026-08-05 · DOI 10.3389/fimmu.2026.1918429
Mateusz Kciuk, Damian Kołat, Katarzyna Wanke, Renata Kontek
The landscape of immunotherapy in oncology has markedly advanced with the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, fundamentally reshaping cancer treatment by potentiating anti-tumor immune responses. PD-1/PD-L1 blockade agents, such as FDA-approved nivolumab, pembrolizumab, and dostarlimab, have demonstrated significant clinical efficacy across various malignancies. Additionally, investigational agents like envafolimab, a novel PD-L1 inhibitor, are currently under clinical evaluation for efficacy and safety in solid tumors. This review examines the emerging data on envafolimab and discusses strategies to optimize its therapeutic impact, including combination regimens and personalized approaches. Tailoring treatments based on individual genetic, immunological, and microbiome profiles holds the potential to enhance response rates and the durability of outcomes. The integration of these factors is pivotal in advancing the precision and success of immunotherapy in oncology.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Kciuk, M., Kołat, D., Wanke, K., et al. (2026). Envafolimab – novel anti-PD-1/PD-L1 antibody in cancer treatment. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1918429